Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Organon & Co. (OGN)
:OGN
Holding OGN?
Track your performance easily
OGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.87 - $23.10
Previous CloseN/A
Volume728.75K
Average Volume (3M)4.03M
Market Cap
$4.17B
Enterprise Value$12.96B
Total Cash (Recent Filing)$319.00M
Total Debt (Recent Filing)$70.00M
Price to Earnings (P/E)3.2
Beta0.67
Next Earnings
Feb 13, 2025EPS Estimate
0.87Last Dividend Ex-Date
Nov 12, 2024Dividend Yield6.92%
Share Statistics
EPS (TTM)5.04
Shares Outstanding257,538,880
10 Day Avg. Volume2,902,376
30 Day Avg. Volume4,031,536
Standard Deviation0.12
R-Squared0.09
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.65
Price to Cash Flow (P/CF)7.40
P/FCF Ratio5.20
Enterprise Value/Market Cap3.11
Enterprise Value/Revenue2.02
Enterprise Value/Gross Profit3.46
Enterprise Value/Ebitda10.23
Forecast
1Y Price Target
$20.17Price Target Upside24.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Organon News
PremiumCompany Announcements
Organon’s VTAMA Cream FDA Review Extended to 2025
PremiumCompany Announcements
Organon & Co. Reports Strong Third Quarter 2024 Results
PremiumCompany Announcements
Organon Posts Strong Q3 2024 Financial ResultsBulls Say, Bears Say
Bulls Say
Product LaunchNexplanon is expected to launch a 5-year indication, with management projecting sales to surpass $1 billion.
Regulatory ApprovalVtama's approval for pediatric use in mild, moderate, and severe disease positions it as the only topical product with this label.
Revenue GrowthSales growth is anticipated from VTAMA, Emgality, and women's health brands, contributing positively to the company's financial performance.
Bears Say
EarningsThe price objective is lowered to $15 from $17, influenced by a delay in VTAMA label expansion.
Financial PerformanceA strengthening USD could create a currency headwind, affecting 75% of OGN revenue which is ex-US.
Growth OutlookBusiness development likely to be muted until 2026 as the company focuses on its balance sheet.
---
Ownership Overview
0.20% Insiders
22.01% Mutual Funds
0.91% Other Institutional Investors
46.73% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OGN FAQ
What was Organon & Co.’s price range in the past 12 months?
Organon & Co. lowest stock price was $13.87 and its highest was $23.10 in the past 12 months.
What is Organon & Co.’s market cap?
Organon & Co.’s market cap is $4.17B.
When is Organon & Co.’s upcoming earnings report date?
Organon & Co.’s upcoming earnings report date is Feb 13, 2025 which is in 26 days.
How were Organon & Co.’s earnings last quarter?
Organon & Co. released its earnings results on Oct 31, 2024. The company reported $0.87 earnings per share for the quarter, missing the consensus estimate of $0.903 by -$0.033.
Is Organon & Co. overvalued?
According to Wall Street analysts Organon & Co.’s price is currently Undervalued.
Does Organon & Co. pay dividends?
Organon & Co. pays a Quarterly dividend of $1.12 which represents an annual dividend yield of 6.92%. See more information on Organon & Co. dividends here
What is Organon & Co.’s EPS estimate?
Organon & Co.’s EPS estimate is 0.87.
How many shares outstanding does Organon & Co. have?
Organon & Co. has 257,538,880 shares outstanding.
What happened to Organon & Co.’s price movement after its last earnings report?
Organon & Co. reported an EPS of $0.87 in its last earnings report, missing expectations of $0.903. Following the earnings report the stock price went up 4.711%.
Which hedge fund is a major shareholder of Organon & Co.?
Among the largest hedge funds holding Organon & Co.’s share is Slate Path Capital LP. It holds Organon & Co.’s shares valued at 47M.
---
Organon Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.17 (24.66% Upside)
$20.17 (24.66% Upside)
Blogger Sentiment
Bullish
OGN Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.16%
12-Months-Change
Fundamentals
Return on Equity
263.89%
Trailing 12-Months
Asset Growth
15.80%
Trailing 12-Months
Company Description
Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its two operating segments are the Organon Products segment and the Merck Retained Products segment. It operates in the United States, China, Japan, Korea, and countries in Europe.
---
OGN Company Deck
---
OGN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong revenue growth, strategic acquisitions, and solid free cash flow. However, there were some challenges related to adjusted EBITDA margin pressure and pricing headwinds.Read More>---
OGN Stock 12 Month Forecast
Average Price Target
$20.17
▲(24.66% Upside)
Technical Analysis
Heron Therapeutics
―
Supernus Pharmaceuticals
―
Perrigo Company
―
Pacira Pharmaceuticals
―
Dr Reddy's Laboratories
―
AstraZeneca
―
Best Analysts Covering OGN
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
+8.49%
reiterated a sell rating last month
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +8.49% per trade.
---